European Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 23 · Tue 17 Nov 

Trials

2025-522310-24-00

EU Clinical Trials Information System

Trial ID
T-ctis-2025-522310-24-00
Registry
EU Clinical Trials Information System
CTIS number
2025-522310-24-00
Asset
brenipatide (LY3537031)
Sponsor, as registered
Eli Lilly & Co.
Phase
Therapeutic confirmatory (Phase III)
Indication
Depressive Disorder, Major
Status
Authorised
Start date
18/09/2026
Primary completion
CTIS does not publish one.
Member states concerned
Germany, Greece, Poland, Spain
Sites
36

Member states whose regulator has a decision on this trial.

euclinicaltrials.euctis registryverified 2026-10-19

Notes on the record

Supersedes the T-ctis-2025-522310-24-00 row verified 2026-10-13. No CSV field changed versus the row verified 2026-10-13; row refreshes verification and records trialEvents ES START_OF_TRIAL 2026-10-14 (first in Spain) and msc[Spain].mscPublicStatusCode 2 -> 3 (code recorded verbatim, not decoded). Recruitment start: DE 2026-10-01, PL 2026-10-08, GR and ES none. Fields read from the CTIS public API retrieve record on 2026-10-19 17:32 CEST (publishDate 2026-10-15T03:40); site_count is the sum of trialSites across authorizedPartsII; codes not decoded; no primary completion date published.

Company

Through brenipatide (LY3537031): Lilly

Cited in

Issues quoting 2025-522310-24-00 in their own text.

Record history